Display options
Cite
Ogren SO, Hall H, Köhler C, et al. Die selektiven antidopaminergen Eigenschaften von Remoxiprid, einem neuen möglichen antipsychotischen Wirkstoff. [Selective antidopaminergic properties of remoxiprid, a new potential antipsychotic agent]. Arzneimittelforschung. 1985;35(8):1227-31
Ogren, S. O., Hall, H., Köhler, C., Magnusson, O., & Florvall, L. (1985). Die selektiven antidopaminergen Eigenschaften von Remoxiprid, einem neuen möglichen antipsychotischen Wirkstoff. [Selective antidopaminergic properties of remoxiprid, a new potential antipsychotic agent]. Arzneimittel-Forschung, 35(8), 1227-31.
Ogren, S O, et al. "Die selektiven antidopaminergen Eigenschaften von Remoxiprid, einem neuen möglichen antipsychotischen Wirkstoff." [Selective antidopaminergic properties of remoxiprid, a new potential antipsychotic agent]. Arzneimittel-Forschung vol. 35,8 (1985): 1227-31.
Ogren SO, Hall H, Köhler C, Magnusson O, Florvall L. Die selektiven antidopaminergen Eigenschaften von Remoxiprid, einem neuen möglichen antipsychotischen Wirkstoff. [Selective antidopaminergic properties of remoxiprid, a new potential antipsychotic agent]. Arzneimittelforschung. 1985;35(8):1227-31. German. PMID: 2866774.
Copy Download .nbib Format: NLM
Share it on

Arzneimittelforschung. 1985;35(8):1227-31.

[Selective antidopaminergic properties of remoxiprid, a new potential antipsychotic agent].

Arzneimittel-Forschung

[Article in German]
S O Ogren, H Hall, C Köhler, O Magnusson, L Florvall

PMID: 2866774

Abstract

The pharmacology of S-(-)-3-bromo-2, 6-dimethoxy-N-(1-ethyl-2-pyrrolidinylone-ethyl)-benzamide (remoxipride), a new neuroleptic compound belonging to the benzamide group, has been thoroughly investigated using a number of different techniques. The compound blocks apomorphine-induced stereotypies and hyperactivity, indicating potent antidopaminergic activity. However, in contrast to many other antidopaminergic compounds, remoxipride induces only weak and atypical catalepsy, which indicates that remoxipride might exert less antidopaminergic side effects than other neuroleptic drugs. In vivo receptor binding studies using 3H-spiperone show that remoxipride preferentially blocks dopamine receptors only are blocked to 60% even at very high doses. In vitro receptor binding studies show that remoxipride is devoid of affinity for receptors other than the dopamine D2 receptors except at higher concentrations. These results indicate that remoxipride should be a clinically effective neuroleptic compound exerting less extrapyramidal side effects than the neuroleptics currently used.

Similar articles

Substances

MeSH terms

Publication Types